Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
10,079 results
- Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- DAISYIndependent statistical analysis of A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- dal-GenEIndependent statistical analysis of Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- DAPHNEIndependent statistical analysis of Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DAPPERIndependent statistical analysis of Depression and Pain Perseverance Through Empowered Recovery Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04091347).
- Daprodustat Bioequivalence and Food Effect Study: Complete Statistical AnalysisIndependent statistical analysis of Daprodustat Bioequivalence and Food Effect Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03493386).
- DAR-PIAIndependent statistical analysis of DAR-901 TB Booster Vaccine to Prevent TB in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02712424).
- Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DARE-CIndependent statistical analysis of DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01743521).
- Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504153).
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00423735).
- Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Data Analysis for Drug Repurposing for Effective Alzheimer’s Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol: Complete Statistical AnalysisIndependent statistical analysis of Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- DATASIndependent statistical analysis of DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00157820).
- DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: Complete Statistical AnalysisIndependent statistical analysis of DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03825315).
- DAYBREAK-ALZIndependent statistical analysis of A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: Complete Statistical AnalysisIndependent statistical analysis of DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Daytime vs. Delayed Eating Among Obese Individuals: Complete Statistical AnalysisIndependent statistical analysis of Daytime vs. Delayed Eating Among Obese Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03354169).
- DB2113361Independent statistical analysis of the randomized phase 3 DB2113361 trial evaluating UMEC/VI 125/25 µg and its components in chronic obstructive pulmonary disease, with emphasis on repeated-measures analysis of trough FEV1.
- DB2113373Complete statistical analysis of the phase 3 DB2113373 trial of UMEC/VI 62.5/25 µg, its components, and placebo in chronic obstructive pulmonary disease, including trial design, FEV1 methodology, mixed-effects modeling, reported estimates, confidence…
- DBAIndependent statistical analysis of The Use of Trifluoperazine in Transfusion Dependent DBA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03966053).
- DBSIndependent statistical analysis of DBS for Home Monitoring in Children With Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01931397).
- DCLP3Independent statistical analysis of The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- DCLP4Independent statistical analysis of The International Diabetes Closed Loop (iDCL) Trial: Protocol 4: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04436796).
- DDxIndependent statistical analysis of Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DEIndependent statistical analysis of Effects of Robotic Versus Manually-Assisted Locomotor Training for Individuals With Incomplete Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DEARIndependent statistical analysis of Dose Escalation and Remission (DEAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00652145).
- DEBRAIndependent statistical analysis of Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- DECIFERIndependent statistical analysis of DECIFER: Depression and Citalopram In First Episode Recovery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01041274).
- Decision Aid for Therapeutic Options In Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Decision Aid for Therapeutic Options In Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02326597).
- Decision Making Tool for Firearm Storage: Complete Statistical AnalysisIndependent statistical analysis of Decision Making Tool for Firearm Storage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06382194).
- Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness: Complete Statistical AnalysisIndependent statistical analysis of Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decision-aid on Breast Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Decision-aid on Breast Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03097653).
- Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00903760).
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00382200).
- Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: Complete Statistical AnalysisIndependent statistical analysis of Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Deep Brain Stimulation for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Deep Brain Stimulation for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00617162).
- DEEPBLOCKIndependent statistical analysis of Deep Neuromuscular Block for Laparoscopic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03034577).
- DeFACTOIndependent statistical analysis of Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01233518).
- DEFEAT-AKIIndependent statistical analysis of Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04633889).
- DEFEAT-PEIndependent statistical analysis of Detect Fluid Early From Intra-thoracic Impedance Monitoring: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00916929).
- Defibrotide TMA Prophylaxis Pilot Trial: Complete Statistical AnalysisIndependent statistical analysis of Defibrotide TMA Prophylaxis Pilot Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03384693).
- DEFINEIndependent statistical analysis of Endophenotype for Alcohol Misuse in Healthy Minority Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00256451).
- DEFINE AFibIndependent statistical analysis of DEFINE AFib (Atrial Fibrillation): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04926857).
- DEFINE-CABPIndependent statistical analysis of Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…